Genomic Urine Testing Market Forecast to Reach USD 319.14 Million by 2034

Market Overview

Genomic urine testing is transforming diagnostic capabilities. It enables the early detection of serious diseases such as kidney disorders, diabetes, urinary tract infections, liver conditions, and especially bladder cancer. These tests analyze urine samples for genetic mutations that can indicate disease well before physical symptoms emerge, offering an edge in preventive and personalized healthcare.

Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5779

Unlike conventional urine tests, genomic versions offer insights into tumor biology, recurrence risks, and treatment responses. This makes them essential for early diagnosis and patient-specific therapeutic planning, helping to improve survival outcomes and reduce healthcare costs.

Key Market Insights

• The market was valued at USD 148.23 million in 2024.

• It is projected to grow at a CAGR of 7.94% from 2025 to 2034.

• By 2034, the market is expected to surpass USD 319.14 million.

• North America currently holds the largest market share.

• The Asia Pacific region is forecasted to grow at the fastest pace over the next decade.

Current Market Trends

India’s Push for Genomic Innovation

In January 2025, the Indian Biological Data Centre (IBDC) initiated efforts to make genetic data more accessible. By supporting tailored genomic tools for the Indian population, this initiative enhances precision medicine research and bolsters India’s standing in the global genomics industry.

Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5779

Development of Point-of-Care TB Testing

In April 2025, Fujirebio Holdings and its subsidiary Fluxus, Inc., received a $4.5 million grant from the GHIT Fund to develop an ultra-sensitive POC urine test for tuberculosis. This innovative project will increase access to accurate TB diagnostics in low-resource settings.

AI Integration in Genomic Urine Testing

Artificial intelligence is reshaping genomic urine testing. It helps process massive genomic datasets with greater accuracy, speed, and efficiency. AI algorithms assist in identifying mutations and sequencing errors, making diagnostic results more precise.

For example, in April 2025, GeneDx announced the acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. This move will combine decentralized testing models with centralized AI insights, advancing the field of personalized medicine.

Market Drivers

Rising Incidence of Bladder Cancer

The growing elderly population, combined with smoking and occupational exposure to carcinogens, has led to a rise in bladder cancer cases. These trends significantly increase the demand for early, non-invasive diagnostic tools like genomic urine tests.

Role of Hospital Pharmacies

Hospital pharmacies lead the market in 2024 due to their integral role in managing patient medications, ensuring proper drug compounding, and optimizing treatment plans. Their close coordination with prescribers enhances the efficacy of test-based medication management.

Meanwhile, specialty pharmacies are expected to experience the fastest growth due to their role in managing complex or chronic conditions that require tailored treatment and frequent monitoring.

If you have any questions, please feel free to contact us at [email protected] 

Market Restraints

High Costs of Genomic Testing

Despite their potential, genomic urine tests are expensive—often 2 to 3 times the cost of conventional tests. The large volumes of data they generate also require advanced storage and analytical systems. These cost-related barriers can limit widespread adoption, especially in developing regions.